Zofingen, 1 June 2012 -- The Board of Directors of Siegfried Holding AG (SIX: SFZN) appointed Dr. René Imwinkelried, Ph.D., the company’s new Head Research & Development and member of the Executive Com- mittee. He is currently Head of Technical Development Small Molecules at Roche in Basel. René Imwinkelried will start in his new function on September 1st, 2012.
Following a Ph.D. degree in organic chemistry from the Swiss Federal Institute of Technology (ETH) Zurich, René Imwinkelried completed a postdoctoral fellowship at both Colorado State University and Harvard University. Prior to his current position at Roche, he executed various R&D functions at Lonza between 1991 and 2004 and held the position of Head of Global Chem- ical and Physical Sciences at the US pharmaceutical company Schering-Plough from 2004 to 2010.
He succeeds Wolfgang Wienand, Ph.D., who held this position since August 2010 and will now focus on further developing Strategy and Mergers & Acquisitions in the Executive Committee and on his responsibility for Legal and IP Management. Wolfgang Wienand will continue to exe- cute both functions until René Imwinkelried joins Siegfried.
Change in the Board of Directors
For personal reasons, Beat In-Albon, Ph.D., has with immediate effect resigned from the Board of Directors of Siegfried Holding AG. The Board of Directors and Management express their gratitude to Beat In-Albon for his cooperation in various committees and his contribution toward the development of the Siegfried Group.
For further informaton:
Peter Gehler, Head Corporate Center
peter.gehler@siegfried.ch
Tel. +41 (0)62 746 11 44
Mobile +41 (079) 416 41 16
Fax +41 (0)62 746 11 03
Siegfried Holding AG
Untere Brühlstrasse 4
CH-4800 Zofingen
Tel. +41 (0)62 746 11 11
Fax +41 (0)62 746 11 03
www.siegfried.ch
About Siegfried
The Siegfried Group is active worldwide in the field of Life Sciences with production facilities located in Switzerland, Malta and the USA. At the end of 2011, Siegfried reported annual sales of CHF 328 million and employes approxi- mately 850 employees. Siegfried Holding AG is listed on the Swiss Exchange (SIX: SFZN).
Siegfried is active in both the primary and secondary production of drugs. The company develops and manufactures active pharmaceutical ingredients for the research-based pharmaceutical industry as well as the corresponding inter- mediate steps and controlled substances, and provides development and production services for drugs in finished dosage forms including sterile filling.
